Article Sidebar
Published:
Mar 16, 2019Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Evaluation of clinical effectiveness of paclitaxel and ursolic acid co-loaded liposomes as enhanced treatment for head and neck squamous cell carcinoma
Abstract
Methods: Co-loaded liposomes of PTX and UA (UA-PTX-LiP) were prepared by thin-film hydration method. Their size and loading efficiency were determined using dynamic light scattering (DLS) technique and high performance liquid chromatography (HPLC), respectively. The effectiveness of UAPTX-LiP against HSC-3 human head and neck cancer cell-lines was compared with that of PTX liposome (PTX-LiP) using systemic cell-based in vitro evaluation with MTT assay. Fluorescent microscopy was used for cell uptake studies.
Results: The size of the prepared UA-PTX-LiP was 126.5 ± 3.22 nm. The ratiometric system for PTX and UA as liposom es revealed significantly enhanced cytotoxicity, with comparatively lower IC50, whencompared to individual PTX-Lip. Fluorescent microscopy revealed the internalization ability of UA-PTXLiP by targeted delivery of PTX in HSC-3 human head and neck cancer cell-line.
Conclusion: These results show that UA-PTX-LiP successfully enhances the therapeutic potential and clinical outcomes of PTX in head-and-neck cancer, and also demonstrate the useful effect of combination of UA and PTX in chemotherapy.
Keywords: Paclitaxel, Ursolic acid, Combination chemotherapy, Head-and-neck squamous cancer
